Mode
Text Size
Log in / Sign up
Phase 3 Completed N=17 Randomized Double-blind Treatment

Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS

Exertional Heat Stroke
Source: ClinicalTrials.gov NCT03600376 ↗
Enrolled (actual)
17
Serious AEs
17.7%
Results posted
Apr 2021
Primary outcomePrimary: Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 [Time Frame: 90 Minutes Post-randomization] — 4; 2 Participants
◆ Published Evidence
Emerging
6citations · ~2 / year
Clinical Spectrum of Pediatric Heat Illness and Heatstroke in a North American Desert Climate.
Pediatric emergency care · 2022 · Likely link

Summary

A double-blind, parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) compared to current Standard of Care (SOC) for EHS.

Linked Publications

  • Clinical Spectrum of Pediatric Heat Illness and Heatstroke in a North American Desert Climate.
    Pediatric emergency care · 2022 · 6 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 [Time Frame: 90 Minutes Post-randomization]
4; 2
SECONDARY
Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]
1; 0; 1; 0; 1; 0

Eligibility Criteria

Inclusion Criteria: Core body temperature of greater than or equal to 40.0 degrees C (104 degrees F); recent history of exertional activity; GCS score less than 13; tachycardia - Exclusion Criteria: clinical severe infection; hyperthermia secondary to another condition; endotracheal intubation;; sedative drugs administered prior to or at time of study entry; likelihood of head trauma within 6 months pre-study; positive pregnancy test; history of myocardial infection within 30 days; history of seizure disorder or epilepsy; concomitant or prior use of calcium channel blockers. -
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03600376) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search